Current evidence for adjunct pyridoxine (vitamin B6) for the treatment of behavioral adverse effects associated with levetiracetam: A systematic review

Besag, Frank; Vasey, Michael J.; Sen, Arjune

doi:10.1016/j.yebeh.2022.109065

Cited by 4 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SV2A is an integral membrane protein found in the vesicles of almost all synaptic terminals, regardless of neurotransmitter content and its expression is similar on both glutamatergic and GABAergic terminals ( 3 , 4 ). LEV also modulates AMPA receptor channels, with result of decreased kainate and AMPA -induced excitatory currents ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

“…Today, it is one of the most prescribed AED, due to its favourable efficacy and few drug-drug interactions. Several clinical trials confirmed its efficacy for multiple seizure types, status epilepticus and electrical status epilepticus during slow-wave sleep (ESES) ( 5 ). Besides antiepileptic effect, LEV also has antiepileptogenic, neuroprotective, anti-inflammatory and anti-oxidant effects ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Levetiracetam for Childhood Epilepsies

Catibusic,

Uzicanin,

Salihbegovic

et al. 2024

Med Arch

View full text Add to dashboard Cite

Background: Levetiracetam (LEV) is a broad spectrum second-generation antiepileptic drug (AED). Objective: The objective of the study was to investigate the efficacy and safety of levetiracetam for childhood epilepsies. Methods: This is single, tertiary centre observational, prospective study, that included paediatric patients who were treated with levetiracetam at Paediatric hospital University Clinical Centre Sarajevo, during the period of 15 years (2008-2022). Inclusion criteria were: paediatric patients age > 1 month, diagnosed with epilepsy according to International League Against Epilepsy. After the introduction of levetiracetam, each patient has been followed up at least 12 months. According to the outcome the patients were divided into 5 groups: seizure reduction >50%, seizure reduction <50%, complete seizure freedom, the same number of seizures and increased number of seizures. From these groups two intergroups have been formed: responders (seizure reduction >50% and complete seizure freedom) and non-responders (seizure reduction <50%, the same number of seizures and increased number of seizures). Results The study enrolled 259 patients (141 female and 118 male), with mean age 7 years (3,0–12.0). Comorbidities were present at 129/259 (49.8%) patients. After 12 months of treatment, 25/259 (9.7%) patients had seizure reduction >50%, 30/259 (11.6%) patients had seizure reduction <50%, 154/259 (56.5%) patients had achieved seizure freedom, 31/259 (12%) patients had same number of seizures, while 19/259 (7.3%) patients had increased number of seizures. Seizure frequency between responders and non-responders, before treatment and after 12 months of treatment was statistically significant (p<0.001). Discussion: Non responders had the best outcome with ditherapy (30/79; 38%), while responders had the best outcome with monotherapy (161/180;89.4%). Conclusion: Levetiracetam is efficient antiepileptic drug for different types of epilepsies in childhood, used as mono, di or polytherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%